Pregnancy on Adalimumab for Psoriasis
Yes, pregnancy is an option for patients with psoriasis on adalimumab, though the decision requires careful risk-benefit assessment prioritizing maternal disease control against potential fetal exposure. 1
Key Evidence from FDA Drug Label
The FDA label for adalimumab provides the most authoritative guidance: Available studies do not reliably establish an association between adalimumab and major birth defects. 1 The OTIS/MotherToBaby Pregnancy Registry (2004-2016) showed a 10% rate of major birth defects with first-trimester adalimumab exposure in 221 pregnant women with RA or Crohn's disease, compared to 7.5% in 106 unexposed women with the same diseases. Critically, there was no pattern of specific birth defects, which is reassuring 1.
Clinical Decision Framework
Before Conception
- Ideally, achieve disease remission before attempting pregnancy 2
- Controlling severe or unstable psoriasis is essential to maintain maternal health 2
- The 2017 British Association of Dermatologists guidelines emphasize that most pregnancies in women taking biologic therapy at conception have successful outcomes 2
During Pregnancy
Adalimumab can be continued during pregnancy when maternal disease control necessitates it. The evidence supports this approach:
- Adalimumab crosses the placenta after 20 weeks of gestation and does not interfere with organogenesis 3
- More recent gastroenterology guidelines (2024) state that anti-TNF medications like adalimumab do not increase the risk of pregnancy complications and lead to fewer neonatal complications, supporting the need for maintaining remission 3
- The 2011 AAD guidelines note adalimumab is FDA pregnancy category B, with no congenital anomalies reported in babies born to women taking adalimumab during trials 4
Important Caveats and Pitfalls
Placental transfer considerations:
- Adalimumab is actively transferred across the placenta during the third trimester 1
- Infants exposed after 20 weeks should not receive live vaccines for the first 6 months due to potential immunosuppression 3
Conflicting older evidence:
- The 2009 BAD guidelines recommended avoiding pregnancy on biologics and stopping therapy if pregnancy discovered 5
- However, this predates substantial safety data and the 2017 BAD guidelines provide updated, more permissive recommendations 2
One concerning case report:
- A 2020 case report documented fetal acrania (exencephaly) in a pregnant woman taking adalimumab 6
- However, this patient also lacked folic acid supplementation, a known risk factor for neural tube defects
- This represents a single case and does not establish causation
Practical Management Algorithm
Pre-pregnancy counseling: Discuss that most pregnancies on adalimumab have successful outcomes, but risks cannot be fully quantified 2
If disease is well-controlled: Consider stopping adalimumab when planning pregnancy or at pregnancy confirmation 5
If disease is severe/unstable: Continue adalimumab throughout pregnancy, as uncontrolled maternal disease poses greater risks (preterm delivery, low birth weight, small for gestational age) 1
Timing consideration: If continuing therapy, some clinicians stop after 30 weeks to minimize fetal drug levels at delivery, though this must be balanced against maternal disease flare risk 5
Neonatal care: Coordinate with pediatrics regarding delayed live vaccine administration for 6 months if exposure occurred after 20 weeks 3
Breastfeeding
The 2009 BAD guidelines recommend avoiding breastfeeding on adalimumab, though limited evidence suggests infliximab is not excreted in breast milk 5. More recent data from IBD literature suggests most biologics are safe during breastfeeding 3.
The critical principle: Maintaining maternal disease remission during pregnancy often outweighs theoretical fetal risks from adalimumab exposure, as active psoriasis itself poses documented pregnancy risks.